Aureus Pharma Announces Renewal and Expansion of Licensing
News Nov 13, 2007
Aureus Pharma's target-family-based AurSCOPE knowledge databases contain quantitative biological activity data which has been mined from the scientific literature. By understanding existing structure activity relationships, and the overall pharmacological space associated with a target/ligand, researchers can better design and prioritize experiments.
"We are very pleased that Bristol-Myers Squibb has chosen Aureus Pharma as a partner for knowledge based drug discovery," commented Jason Theodosiou, CEO of Aureus Pharma.
"Bristol-Myers Squibb has been an important customer since 2002 and we regard their renewal and license extension as confirmation that our knowledge database solutions are meeting the needs of the world´s leading pharmaceutical companies," Jason said.
Researchers at the Crick and Imperial College London have generated malaria parasites resistant to a promising new class of candidate antimalarial drugs. By analyzing the structural changes behind the resistance, they identified novel compounds that were immune to this mechanism of resistance.READ MORE